Navigation Links
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed results from the Company's recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association Meeting in Colorado Springs. These independent podium presentations will be given by leading clinical research urologist principal investigators from the clinical trials. Further specific details on the upcoming presentations will be announced at a later date.

The Company has completed a series of studies of the safety and efficacy of NX-1207 for BPH, including two Phase 1-2 studies and a Phase 2 study as well as several follow-up studies of patients for up to 3 1/2 years after NX-1207 treatment. The Company's recently completed prospective randomized placebo controlled Phase 2 U.S. study confirmed the positive efficacy and safety results for NX-1207 from earlier studies. After 3 months, patients treated with NX-1207 had a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement was significantly greater than the 3.5 to 5 points typically reported for currently approved drugs for BPH. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. In particular, patients given NX-1207 had no (0%) significant sexual side effects. Follow-up studies have provided data showing that NX-1207 can provide enduring benefits of up to 42 months or more following treatment.

The AUA Symptom Score is a standardized and widely accepted questionnaire used to assess the severity of BPH symptoms and the efficacy of treatments for BPH. The AUA Score consists of seven questions relating to frequency of problems with urination such as urgen cy, starting and stopping, straining, poor flow rate, incomplete emptying of the bladder and getting up at night to urinate (nocturia). The patient scores the frequency of each problem on a scale of 0 (not at all) to 5 (almost always). The resulting AUA Symptom Score ranges from 0 points (no symptoms) to 35 points (severe). A score of 8 points or more indicates moderate to severe symptoms warranting consideration of treatment options.

BPH is a common disorder of older men, afflicting approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact

Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com


'"/>




Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... 19, 2017 , ... DMG Productions, producers of the award ... an upcoming episode, slated to air fourth quarter 2017. Check your local listings ... a company committed to supporting dentistry using the most technologically advanced restorative materials ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Curl Keeper® ... of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second year in ... for hair stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: ... both their parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of ... from Long Island, New York. , Published by Christian Faith Publishing, Dale Anthony and ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... ... asset protection services and financial consultations to communities throughout the greater DC region, ... K9 with the goal of rescuing local animals and training them to be ...
Breaking Medicine News(10 mins):